Weiss Ratings Reaffirms Hold (C) Rating for Bausch Health Cos (NYSE:BHC)

Key Points

• Weiss Ratings has reaffirmed a "hold (c)" rating for Bausch Health Cos (NYSE:BHC), indicating a cautious outlook on the company's stock performance.
• Bausch Health's stocks have seen a recent trading decline of 0.5%, with a current price of $6.36, compared to a 52-week range between $4.25 and $9.85.
• Insider transactions have increased significantly, with Director John Paulson acquiring over 34 million shares, boosting his ownership by 96.35% and indicating strong insider confidence in the company's future.

Bausch Health Cos (NYSE:BHC - Get Free Report)'s stock had its "hold (c)" rating restated by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 20th. Four research analysts have rated the stock with a Hold rating, According to MarketBeat, Bausch Health Cos has a consensus rating of "Hold" and an average target price of $9.00.

Bausch Health Cos Trading Down 0.5%

NYSE BHC traded down $0.03 during trading on Wednesday, hitting $6.36. The company had a trading volume of 902,953 shares, compared to its average volume of 2,551,972. Bausch Health Cos has a one year low of $4.25 and a one year high of $9.85. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. The company's fifty day moving average is $6.90 and its 200-day moving average is $6.04. The company has a market cap of $2.36 billion, a price-to-earnings ratio of 24.46 and a beta of 0.43.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07). The company had revenue of $2.57 billion for the quarter, compared to analysts' expectations of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Bausch Health Cos will post 4.41 earnings per share for the current year.

Insider Transactions at Bausch Health Cos

In other news, Director John Paulson purchased 34,721,118 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the purchase, the director directly owned 70,755,869 shares in the company, valued at approximately $636,802,821. This trade represents a 96.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have bought 37,964,167 shares of company stock valued at $333,757,793. Insiders own 19.97% of the company's stock.

Institutional Investors Weigh In On Bausch Health Cos

Several institutional investors and hedge funds have recently made changes to their positions in the company. Goldentree Asset Management LP increased its position in shares of Bausch Health Cos by 13.2% during the second quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company's stock valued at $227,848,000 after acquiring an additional 4,004,889 shares in the last quarter. Paulson & CO. Inc. boosted its stake in Bausch Health Cos by 24.0% during the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company's stock valued at $218,393,000 after purchasing an additional 6,352,667 shares during the last quarter. Nomura Holdings Inc. lifted its holdings in shares of Bausch Health Cos by 106.2% during the first quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company's stock valued at $151,366,000 after purchasing an additional 12,050,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Bausch Health Cos by 0.5% during the first quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock valued at $76,152,000 after purchasing an additional 61,621 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. lifted its holdings in shares of Bausch Health Cos by 14.9% during the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company's stock valued at $52,005,000 after purchasing an additional 1,010,987 shares in the last quarter. Institutional investors own 78.65% of the company's stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.